personalized neoantigen vaccine
Vaccineexperimental
Clinical trial activity
46 trials · 45 clinical orgs · 0 marketing orgs
Phase 1
32
Phase 2
9
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01885702)
Timeline
Indications
Studied for
- Antigens, Neoplasm · Early Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 2/Phase 3
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Cholangiocarcinoma · Early Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Conjunctival Neoplasms · Phase 1
- Drug Therapy · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Gastrointestinal Neoplasms · Phase 1/Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Intestinal Neoplasms · Phase 1
- Leukemia, Myeloid, Acute · Early Phase 1
- Lung Neoplasms · Phase 1
- Melanoma · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
- Translocation, Genetic · Early Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- personalized neoantigen vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07298200 | Phase 1 | Dec 31, 2025 | Government of China, Nanjing University |
| NCT06913218 | Phase 1 | Jul 22, 2025 | Akeso Pharmaceuticals, Inc., Fudan University |
| NCT07067385 | Phase 1 | Jul 1, 2025 | Jiao Tong University |
| NCT06735508 | Early Phase 1 (Phase 1) | Jan 31, 2025 | Government of China, Shantou University |
| NCT06529822 | Phase 1 | Nov 30, 2024 | Natera, Inc., Washington University in St. Louis |
| NCT06751966 | N/A | Sep 1, 2024 | Nanchang University |
| NCT06751914 | N/A | Sep 1, 2024 | Nanchang University |
| NCT06752044 | N/A | Sep 1, 2024 | Nanchang University |
| NCT06195293 | Phase 1 | Jun 4, 2024 | Guangzhou Medical University |
| NCT06432075 | Early Phase 1 (Phase 1) | Jun 1, 2024 | Wenzhou Medical University |
| NCT06406816 | Early Phase 1 (Phase 1) | May 31, 2024 | Fujian Medical University |
| NCT06195384 | Phase 1 | May 8, 2024 | Guangzhou Medical University |
| NCT06431529 | Early Phase 1 (Phase 1) | Apr 18, 2024 | Jinlin University, Nanjing University |
| NCT06496373 | Phase 1 | Apr 1, 2024 | Jiao Tong University |
| NCT06344156 | Phase 1 | Apr 1, 2024 | Sichuan University |
| NCT06751901 | Phase 2 | Mar 11, 2024 | Nanchang University |
| NCT07002203 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2024 | Bumrungrad International Hospital, Seqker Biosciences, Inc. |
| NCT06499025 | Early Phase 1 (Phase 1) | Feb 1, 2024 | BGI Group, Shenzhen University |
| NCT06341907 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2024 | Wenzhou Medical University |
| NCT06329908 | Early Phase 1 (Phase 1) | Sep 27, 2023 | Sichuan University |
Showing 20 of 46 trials
Page 1 / 3
Organizations
Research & Development (45)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 7 | 0 | 2 | 2019 |
| Nanchang University | Academic/Hospital | 5 | 5 | 2 | 2023 |
| Fudan University | Academic/Hospital | 3 | 2 | 3 | 2012 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 1 | 2019 |
| Washington University in St. Louis | Academic/Hospital | 3 | 3 | 1 | 2019 |
| Guangzhou Medical University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Jiao Tong University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Nanjing University | Academic/Hospital | 2 | 1 | 1 | 2024 |
| Peking University | Academic/Hospital | 2 | 1 | 1 | 2022 |
| Seqker Biosciences, Inc. | For profit | 2 | 2 | 1 | 2022 |
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Sichuan University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Stemirna Therapeutics | For profit | 2 | 2 | 2 | 2022 |
| University of California, San Diego | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Wenzhou Medical University | Academic/Hospital | 2 | 2 | 2 | 2024 |
| Accelerate Brain Cancer Cure | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Akeso Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2025 |
| BGI Group | For profit | 1 | 1 | 1 | 2024 |
| Bumrungrad International Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
45 organizations
Page 1 / 3